ReviewChemical science2026
Molecular engineering of CRISPR/Cas12a: from activity enhancement to exponential signal amplification.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR/Cas12a has emerged as a powerful tool for molecular diagnostics, yet its inherent linear signal output and limited amplification efficiency constrain its detection sensitivity. Conventional approaches that rely on coupling with pre-amplification techniques increase operational complexity and introduce potential uncertainties, thereby hindering clinical translation. This review highlights a paradigm shift: moving beyond the canonical "one-target-one-enzyme" model through molecular engineering to intrinsically enhance the catalytic activity of CRISPR/Cas12a and even achieve exponential signal amplification. We systematically summarize key strategies, including crRNA reprogramming, activator strand engineering, reporter probe design, and reaction environment optimization, that collectively enhance Cas12a's kinetics, specificity, and intrinsic signal output. These integrated engineering approaches enable ultrasensitive, pre-amplification-free detection of both nucleic acids and non-nucleic acid targets, paving the way for the next generation of robust and field-deployable point-of-care diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.